Skip to main content
FDA Updates
Lenvatinib Approved for Use with Everolimus for Treating Advanced Renal Cell Carcinoma
Read More
Online First
“Newer” Ovarian Cancer Genes and Option of Risk-Reducing Salpingo-Oophorectomy
Cristi Radford, MS, CGC
Read More
FDA Updates
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
A Pipeline Preview of 2016 FDA Approvals in Hematology/Oncology
Ryan Beechinor, PharmD, BCPS, CPP, John M. Valgus, PharmD, MHA, BCOP
Read More
FDA Updates
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Monoclonal Antibodies
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala, Medical Writer
Read More
FDA Updates
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Page 174 of 200
Results 1731 - 1740 of 1993